[
  {
    "ts": null,
    "headline": "Buy 3 'Safer' Dividend Kings Of 25 From 53 For January",
    "summary": "53 Dividend Kings offer steady growth across sectors. See why MO, UBSI, and HRL are top picks for January with yields greater than their single-share prices.",
    "url": "https://finnhub.io/api/news?id=1a4d5878f76b071b3de965ed29cf79dc044e68a10ad7d2c3e5c575f591fb07e2",
    "source": "SeekingAlpha",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1736944797,
      "headline": "Buy 3 'Safer' Dividend Kings Of 25 From 53 For January",
      "id": 132400696,
      "image": "https://static.seekingalpha.com/cdn/s3/uploads/getty_images/1706192685/image_1706192685.jpg?io=getty-c-w1536",
      "related": "JNJ",
      "source": "SeekingAlpha",
      "summary": "53 Dividend Kings offer steady growth across sectors. See why MO, UBSI, and HRL are top picks for January with yields greater than their single-share prices.",
      "url": "https://finnhub.io/api/news?id=1a4d5878f76b071b3de965ed29cf79dc044e68a10ad7d2c3e5c575f591fb07e2"
    }
  },
  {
    "ts": null,
    "headline": "Johnson & Johnson: FDA to review TAR-200 dossier",
    "summary": "Johnson & Johnson announced on Wednesday that the U.S. Food and Drug Administration had agreed to review its application for registration of TAR-200, an experimental treatment for bladder cancer.The...",
    "url": "https://finnhub.io/api/news?id=3c56dc18b10597fba8292a4a295d898618caff23b614e429715e2c9017b67d3a",
    "source": "Finnhub",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1736937316,
      "headline": "Johnson & Johnson: FDA to review TAR-200 dossier",
      "id": 132400092,
      "image": "",
      "related": "JNJ",
      "source": "Finnhub",
      "summary": "Johnson & Johnson announced on Wednesday that the U.S. Food and Drug Administration had agreed to review its application for registration of TAR-200, an experimental treatment for bladder cancer.The...",
      "url": "https://finnhub.io/api/news?id=3c56dc18b10597fba8292a4a295d898618caff23b614e429715e2c9017b67d3a"
    }
  },
  {
    "ts": null,
    "headline": "J&J Initiates Bid for FDA Approval of TAR-200 in Bladder Cancer",
    "summary": "By Colin Kellaher Johnson & Johnson has initiated an application seeking Food and Drug Administration approval of its TAR-200 drug-device combination for the treatment of certain patients with...",
    "url": "https://finnhub.io/api/news?id=da08fe5ab36bca8e7af09598c567873ec14f50cd95d895d6e46d1ba6b15577c7",
    "source": "Finnhub",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1736930496,
      "headline": "J&J Initiates Bid for FDA Approval of TAR-200 in Bladder Cancer",
      "id": 132399570,
      "image": "",
      "related": "JNJ",
      "source": "Finnhub",
      "summary": "By Colin Kellaher Johnson & Johnson has initiated an application seeking Food and Drug Administration approval of its TAR-200 drug-device combination for the treatment of certain patients with...",
      "url": "https://finnhub.io/api/news?id=da08fe5ab36bca8e7af09598c567873ec14f50cd95d895d6e46d1ba6b15577c7"
    }
  },
  {
    "ts": null,
    "headline": "New Drug Application initiated with U.S. FDA for TAR-200, the first and only intravesical drug releasing system for patients with BCG-unresponsive high-risk non-muscle-invasive bladder cancer",
    "summary": "Application accepted for U.S. FDA Real-Time Oncology Review based on Phase 2b SunRISe-1 study showing highest single-agent complete response rate of 83.5 percent1RARITAN, N.J., Jan. 15, 2025...",
    "url": "https://finnhub.io/api/news?id=6075170b5edd2d10f3795ec305800a1ed5af5231859db546babeaf8c05207360",
    "source": "Finnhub",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1736928073,
      "headline": "New Drug Application initiated with U.S. FDA for TAR-200, the first and only intravesical drug releasing system for patients with BCG-unresponsive high-risk non-muscle-invasive bladder cancer",
      "id": 132399305,
      "image": "",
      "related": "JNJ",
      "source": "Finnhub",
      "summary": "Application accepted for U.S. FDA Real-Time Oncology Review based on Phase 2b SunRISe-1 study showing highest single-agent complete response rate of 83.5 percent1RARITAN, N.J., Jan. 15, 2025...",
      "url": "https://finnhub.io/api/news?id=6075170b5edd2d10f3795ec305800a1ed5af5231859db546babeaf8c05207360"
    }
  },
  {
    "ts": null,
    "headline": "ClearBridge Value Fund Q4 2024 Commentary",
    "summary": "Strategy outperformed its Russell 1000 Value benchmark during 4Q, as positive contributions from stock selection and sector allocation effects contributed to relative performance.",
    "url": "https://finnhub.io/api/news?id=16104d7a68c2939ee98b902963633ee224985f62212a98b4fd4a0b33be489f73",
    "source": "SeekingAlpha",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1736925600,
      "headline": "ClearBridge Value Fund Q4 2024 Commentary",
      "id": 132399220,
      "image": "https://static.seekingalpha.com/cdn/s3/uploads/getty_images/1072593728/image_1072593728.jpg?io=getty-c-w1536",
      "related": "JNJ",
      "source": "SeekingAlpha",
      "summary": "Strategy outperformed its Russell 1000 Value benchmark during 4Q, as positive contributions from stock selection and sector allocation effects contributed to relative performance.",
      "url": "https://finnhub.io/api/news?id=16104d7a68c2939ee98b902963633ee224985f62212a98b4fd4a0b33be489f73"
    }
  }
]